RxDoctor Payments Data

Alexander Pinkusovich, MD

Psychiatry · Brooklyn, NYNPI 1801850003

Payments from drug & device makers

$94,660in general payments, 2019–2025

Across 342 payments — averaging $276.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$75K
  • Sunovion Pharmaceuticals Inc.$13K
  • AbbVie$5K
  • Alkermes, Inc.$413
  • E.r. Squibb & Sons, L.L.C.$325
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$139
  • plus $462 from 12 others

What the payments were for

  • Consulting fees$5,2005%
  • Speaking & faculty fees$78,53183%
  • Travel & lodging$1,3161%
  • Food & beverage$9,55510%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,660 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$495,385
Medicare patients
965
Services billed
3,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate3,922$6,221,203
NamzaricMemantine Hcl/Donepezil Hcl1,896$1,085,452
LatudaLurasidone Hcl736$1,030,358
Wellbutrin XlBupropion Hcl328$816,792
VraylarCariprazine Hcl133$188,216
Lurasidone Hcl712$168,097
TrintellixVortioxetine Hydrobromide185$86,954
Vilazodone Hcl1,207$75,694
ViibrydVilazodone Hcl210$68,064
FetzimaLevomilnacipran Hcl135$65,486
RexultiBrexpiprazole45$61,734
Effexor XrVenlafaxine Hcl20$32,529
AplenzinBupropion Hbr12$29,811
Memantine Hcl ErMemantine Hcl349$24,857
UbrelvyUbrogepant21$23,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$75,371$6,221,2033,922 claims
AbbVieNamzaric, Vraylar, Viibryd, Fetzima, Ubrelvy$4,857$1,441,0422,419 claims
Sunovion Pharmaceuticals Inc.Latuda$13,093$1,030,358736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →